Entrada Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
152
- Stock Symbol
-
TRDA
- Share Price
-
$4.99
- (As of Monday Closing)
Entrada Therapeutics General Information
Description
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Contact Information
Website
www.entradatx.comCorporate Office
- One Design Center Place
- Suite 17- 500
- Boston, MA 02210
- United States
Corporate Office
- One Design Center Place
- Suite 17- 500
- Boston, MA 02210
- United States
Entrada Therapeutics Stock Performance
As of 16-Nov-2026, Entrada Therapeutics’s stock price is $4.99. Its current market cap is $196M with 39.2M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.99 | $5.10 | $4.11 - $16.45 | $196M | 39.2M | 383K | -$3.84 |
Entrada Therapeutics Financials Summary
As of 30-Sep-2026, Entrada Therapeutics has a trailing 12-month revenue of $3.98M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 72,787 | 118,456 | 258,961 | 219,019 |
| Revenue | 3,977 | 25,421 | 210,782 | 129,013 |
| EBITDA | (167,961) | (153,798) | 50,811 | (321) |
| Net Income | (161,386) | (143,750) | 65,626 | (6,685) |
| Total Assets | 266,880 | 377,378 | 526,321 | 469,192 |
| Total Debt | 47,313 | 50,932 | 59,207 | 68,230 |
Entrada Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Entrada Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Entrada Therapeutics Comparisons
Industry
Financing
Details
Entrada Therapeutics Competitors (33)
One of Entrada Therapeutics’s 33 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Avidity Biosciences | Formerly VC-backed | San Diego, CA | ||||
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| PEP-Therapy | Venture Capital-Backed | Evry Cedex, France | ||||
| Enterome | Venture Capital-Backed | Paris, France | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom |
Entrada Therapeutics Patents
Entrada Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026151958-A1 | Compounds and methods for skipping exon 51 in duchenne muscular dystrophy | Pending | 10-Jan-2025 | ||
| WO-2026136957-A3 | Compounds comprising delivery constructs comprising cyclic cell penetrating peptides for intracellular targeting of oligonucleotides | Pending | 20-Dec-2024 | ||
| WO-2026136957-A2 | Intracellular targeting of oligonucleotides | Pending | 20-Dec-2024 | ||
| WO-2026136946-A1 | Phosphorodiamidate morpholino oligomer conjugate compounds and their use in treating myotonic dystrophy type 1 | Pending | 20-Dec-2024 | ||
| WO-2025151707-A1 | Method for preparing multimers of phosphorodiamidate morpholino oligomers | Inactive | 11-Jan-2024 | C12N15/111 |
Entrada Therapeutics Signals
Entrada Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Entrada Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.91 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Entrada Therapeutics FAQs
-
When was Entrada Therapeutics founded?
Entrada Therapeutics was founded in 2016.
-
Where is Entrada Therapeutics headquartered?
Entrada Therapeutics is headquartered in Boston, MA.
-
What is the size of Entrada Therapeutics?
Entrada Therapeutics has 152 total employees.
-
What industry is Entrada Therapeutics in?
Entrada Therapeutics’s primary industry is Drug Delivery.
-
Is Entrada Therapeutics a private or public company?
Entrada Therapeutics is a Public company.
-
What is Entrada Therapeutics’s stock symbol?
The ticker symbol for Entrada Therapeutics is TRDA.
-
What is the current stock price of Entrada Therapeutics?
As of 16-Nov-2026 the stock price of Entrada Therapeutics is $4.99.
-
What is the current market cap of Entrada Therapeutics?
The current market capitalization of Entrada Therapeutics is $196M.
-
What is Entrada Therapeutics’s current revenue?
The trailing twelve month revenue for Entrada Therapeutics is $3.98M.
-
Who are Entrada Therapeutics’s competitors?
Avidity Biosciences, Dyne Therapeutics, PEP-Therapy, Enterome, and Enterprise Therapeutics are some of the 33 competitors of Entrada Therapeutics.
-
What is Entrada Therapeutics’s annual earnings per share (EPS)?
Entrada Therapeutics’s EPS for 12 months was -$3.84.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process